| Date/App# |
 List of recent Antibodies-related patents |
02/26/15
20150059009 |   Methods for making fully human bispecific antibodies using a common light chain
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc. |
02/26/15
20150057436 |  Humanized antibodies
The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family camelidae.. .
Argen-x Bv |
02/26/15
20150057183 |  Method for the determination of the dna methylation level of a cpg position in identical cells within a tissue sample
Aspects of the present invention relate to the determination of the dna methylation level at one or more cpg position within cells of a defined type in a tissue sample. This methylation level is deduced from the total dna methylation level of all cells of the sample and from the content of said cells of interest.
Epigenomics Ag |
02/26/15
20150056688 |  Dual path immunoassay device
Systems include test cells with sorbent material in a t-shape and defining a first flow path for a solution and a second flow path for a sample, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules located at the junction of the t. A housing houses the sorbent material and defines a first hole adjacent an end of the first flow path for receiving the solution and a second hole adjacent an end of the second flow path for receiving the sample..
Chembio Diagnostics Systems, Inc. |
02/26/15
20150056680 |  Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc. |
02/26/15
20150056655 |  Expression constructs and methods for expressing polypeptides in eukaryotic cells
The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile..
Glenmark Pharmaceuticals S.a. |
02/26/15
20150056640 |  Reagents and methods for detecting a polymorphic protein
The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications..
Rappaport Family Institute For Research In The Medical Sciences |
|
|
02/26/15
20150056635 |  Systems and methods for anti-pax8 antibodies
The present invention is related to the anti-pax8 antibodies, kits, cocktails, and use of anti-pax8 antibodies for detection of cancer.. .
Biocare Medical, Llc |
02/26/15
20150056633 |  Detection of glutathionylated proteins
The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as s-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition.
Universiteit Maastricht |
02/26/15
20150056610 |  Monitoring and inhibiting human immunodeficiency virus infection by modulating hmgb1 dependent triggering of hiv-1 replication and persistence
Compositions and methods for modulating human immunodeficiency virus (hiv) infection involving substances that inhibit the ability of high mobility box 1 (hmgb1) protein to interact with natural killer (nk) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to hmgb1.
Institut Pasteur |
02/26/15
20150056222 | Anti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc. |
02/26/15
20150056221 | Anti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc. |
02/26/15
20150056216 | Antibody combinations and use of same for treating cancer
A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti erbb-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti erbb-2 antibodies exhibiting binding to different epitopes on the erbb-2, at least one of the different epitopes being localized to a dimerization site of the erbb-2, the combination of antibodies being with the combined improved anti-tumor activity.
Yeda Research And Development Co., Ltd. |
02/26/15
20150056214 | Monoclonal antibodies that bind b7h6 and uses thereof
Disclosed are monoclonal antibodies that specifically bind to the b7 family member b7h6, including antibodies capable of inhibiting the interaction of b7h6 with nkp30. Also disclosed are anti-b7h6 antibody-drug conjugates comprising an anti-b7h6 monoclonal antibody conjugated to a therapeutic agent.
Institut National De La Sante Et De La Recherche Medicale |
02/26/15
20150056211 | Heparin-binding epidermal growth factor-like growth factor binding proteins
Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (hb-egf) and neutralize the biological functions of this growth factor.. .
Amgen, Inc. |
02/26/15
20150056209 | Peptide mimotopes to oxidation specific epitopes
Provided herein are peptide mimotopes that are useful for generating antibodies and in the preparation of vaccines and diagnostics for treating and diagnosing coronary artery disease.. .
Medizinsche Universitat Wien |
02/26/15
20150056208 | Novel antibodies
Autoimmune reactions to certain epitopes of self antigens most likely contribute to the development of rheumatoid arthritis. Often these epitopes are citrullinated.
Vilara Ab |
02/26/15
20150056204 | Dr5 receptor agonist combinations
The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of nk cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human dr5, or a cooperative combination of an anti-dr5 antibody and trail.
Amgen Inc. |
02/26/15
20150056201 | Methods for detecting th1 cells
The inventors discovered that the adhesion molecule car, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified carl, a novel car ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in th1 cells.
Eisai R&d Management Co., Ltd. |
02/26/15
20150056200 | Methods for increasing adiponectin
In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-activin a and/or b antibodies, anti-myostatin antibodies, anti-gdf3 antibodies, and anti-bmp7 antibodies.
Acceleron Pharma, Inc. |
02/26/15
20150056188 | Jcv neutralizing antibodies
In one aspect, the disclosure provides neutralizing antibodies against jcv and methods for the treatment of pml. In some embodiments, aspects of the invention relate to an isolated jc-virus neutralizing monoclonal antibody against jcv capsid protein vpi (jcv-vp1).
Biogen Idec Ma Inc. |
02/26/15
20150056187 | Humanized antibodies that recognize alpha-synuclein
The present application discloses humanized 1h7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of lewy body disease..
Neotope Biosciences Limited |
02/26/15
20150056182 | Drug containing carrier into cell for forming immune complex
The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved..
Chugai Seiyaku Kabushiki Kaisha |
02/26/15
20150056135 | Treatment of proliferative disorders using antibodies to psma
Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of psma after first administering a hormonal therapy..
Cornell University |
02/26/15
20150056134 | Nucleic acids encoding human antibodies to sialyl-lewis a
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against sialyl-lewisa (slea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to slea.
Mabvax Therapeutics, Inc. |
02/26/15
20150056132 | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.
Genentech, Inc. |
02/19/15
20150051839 | Method for characterising plasma cell associated diseases
The invention provides a method for characterising a plasma cell associated disease in a patient comprising: (i) providing at least one sample from the patient; (ii) determining in the sample(s) two or more of; (a) the κ:λ free light chain (flc) ratio; (b) the ratio of κ light chains bound to a class of heavy chain:λ light chain bound to the same class of heavy chain (hlcκ:hlc λ ratio); (c) the total amount of flc in the samples and (d) the total amount of κ light chains bound to the heavy chain class plus λ light chains bound to the same heavy chain class (total hlc); (iii) comparing each ratio or amount from (a) (b), (c) and/or (d) to predetermined values and assigning a score to each amount or ratio; and (iv) using the scores to characterise the plasma cell associated disease. Apparatus configured to carry out the method of the invention are also provided.
The Binding Site Group Limited |
02/19/15
20150051380 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.. .
Genentech, Inc. |
02/19/15
20150051106 | Human serum biomarkers of prostate cancer and sars-cov
Anti-carbohydrate antibodies are detected by (a) contacting an array of oligomannose-serum albumin conjugates immobilized on a substrate with an antibody-containing serum sample under conditions wherein tm10 antibodies bind the oligomannose of the conjugates at at least micromolar affinity; and (b) detecting resultant binding of specific antibodies of the sample to the oligomannose of the conjugates, as indicative of the anti-carbohydrate antibodies.. .
Sri International |
02/19/15
20150050723 | Optoelectronic detection system
The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals.
Massachusetts Institute Of Technology |
02/19/15
20150050715 | Stably tethered structures of defined compositions with multiple functions or binding specificities
The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor.
Ibc Pharmaceuticals, Inc. |
02/19/15
20150050668 | Assay for anti-tr antibodies
The present invention relates to a method for determining the presence of anti-tr antibodies in a subject comprising the steps of obtaining a sample from said subject testing the presence of said antibodies in said sample by addition of dner protein or an antigenic part thereof and checking whether said dner protein is bound by any antibodies in said sample such an assay is useful for the diagnosis of paraneoplastic cerebellar degeneration that is associated with hodgkin lymphoma, or, more generally, to type patients suffering from cerebellar ataxia. Also comprised in the invention is a kit for performing such an assay..
Erasmus University Medical Center Rotterdam |
02/19/15
20150050667 | Cell-surface signatures for isolating neurons from cell cultures derived from pluripotent stem cells
The inventors disclose methods and systems that provide for the isolation and purification of neurons directly from heterogeneous cell cultures. The expression of various cell adhesion molecules was examined in pluripotent stem cells.
Becton ,dickinson And Company |
02/19/15
20150050641 | Method for the enumeration of mammalian micronucleated erythrocyte populations, while distinguishing platelets and/or platelet-associated aggregates
A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains dna (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
Litron Laboratories, Ltd. |
02/19/15
20150050293 | Flagellum and anti-flagellum antibody levels in samples as a diagnostic biomarker and therapeutic target for metabolic syndrome
High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome..
Cornell University |
02/19/15
20150050292 | Detection, prevention, and treatment of anthrax and other infectious diseases
Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against bacillus anthracis or other capsulated pathogens.
Regents Of The University Of Minnesota |
02/19/15
20150050286 | Anti-ngf antibodies and methods using same
The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp. |
02/19/15
20150050281 | Methods of treating a tauopathy
The present disclosure provides methods of treating a tauopathy, involving administering an anti-tau antibody. The present disclosure also provides anti-tau antibodies, and formulations comprising same, for use in the methods..
Ipierian, Inc. |
02/19/15
20150050280 | Soluble human m-csf receptor and uses thereof
Methods of using m-csf antibodies to treat macrophage-associated diseases including atherosclerosis and hiv are provided.. .
Xoma Technology Ltd. |
02/19/15
20150050276 | High affinity antibodies that neutralize staphylococcus enterotoxin b
Provided herein are antibodies that specifically bind and neutralize staphylococcus enterotoxin b. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided.
Morphotek, Inc. |
02/19/15
20150050275 | Purification of anti-c-met antibodies
Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.. .
Genentech, Inc. |
02/19/15
20150050273 | Afucosylated anti-fgfr2iiib antibodies
The present invention provides antibodies that bind fgfr2iiib, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind fgfr2iiib, wherein at least 95% of the antibodies in the composition are afucosylated.
Five Prime Therapeutics, Inc. |
02/19/15
20150050271 | Jcv neutralizing antibodies
In one aspect, the disclosure provides neutralizing antibodies against jcv and methods for the treatment of pml. In some embodiments, aspects of the invention relate to an isolated jc-vims neutralizing monoclonal antibody against jcv capsid protein vpi (jcv-vp1).
Biogen Idec Ma Inc. |
02/19/15
20150050270 | Antibodies to bradykinin b1 receptor ligands
The invention provides antibodies that specifically bind to kallidin or des-arg10-kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-kallidin or des-arg10-kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof.
Sanofi |
02/19/15
20150050267 | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc. |
02/19/15
20150050240 | Treatment of fibrosis
This invention is in the field of treatment of fibrosis. In particular, it relates to the treatment of ipf using n-cadherin antibodies.
Novartis Ag |
02/19/15
20150050238 | Treatment of osteoarthritis and pain
The present invention relates to the treatment of osteoarthritis and pain using il-1α and il-1β binding proteins, including anti-il-1α and anti-il-1β antibodies and engineered multivalent and multispecific il-1α and il-1β binding proteins.. .
Abbvie Inc. |
02/19/15
20150050215 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.
Axon Neuroscience Se |
02/12/15
20150045542 | Human antibodies that bind human tnf-alpha and methods of preparing the same
Methylglyoxal (mgo)-modified recombinant tnf-alpha antibodies (e.g., adalimumab) are identified. Mgo modification decreases binding between adalimumab and tnf-alpha.
Abbvie Inc. |
02/12/15
20150045541 | Antibodies for identifying and/or isolating at least one cell population
Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells.
Hoffman-la Roche Inc. |
02/12/15
20150044722 | Siglec-15 antibodies in treating bone loss-related disease
Novel antibodies and antigen binding fragments that specifically binds to siglec-15 are described herein in some embodiments, the antibodies or antigen binding fragments may block the biological activity of siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts the invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.. .
Alethia Biotherapeutics Inc. |
02/12/15
20150044707 | At-home blood pregnancy test kit
Disclosed is an at-home blood pregnancy test kit that can identify the presence of hcg in a blood sample to detect pregnancy in female mammals. The present kit includes a housing having a sample strip that is in fluid communication with a sample pad for holding a blood sample, a test pad, and a conjugate pad. |
02/12/15
20150044704 | Monoclonal antibodies and diagnostic uses thereof
The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (prame), and the synovial sarcoma x breakpoint 2 (ssx-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the prame and ssx-2 antigens and methods of using such antibodies..
Mannkind Corporation |
02/12/15
20150044700 | Anti-gap43 antibody
An anti-gap43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 89 (t89) from a phosphorylated threonine residue at position 89 (pt89) of mouse gap43 set forth in seq id no: 13, and which is capable of specifically detecting a growth cone; an anti-gap43 antibody which is capable of distinguishing a non-phosphorylated serine residue at position 96 (s96) from a phosphorylated serine residue at position 96 (ps96) of mouse gap43, and which is capable of specifically detecting a growth cone; an anti-gap43 antibody which is capable of distinguishing a non-phosphorylated threonine residue at position 172 (t172) from a phosphorylated threonine residue at position 172 (pt172) of mouse gap43, and which is capable of specifically detecting a growth cone; and an immunological analysis method using these anti-gap43 antibodies.. .
Niigata University |
02/12/15
20150044698 | Outer membrane protein 18 as a diagnostic marker for campylobacter
Accurate and fast detection of the presence of campylobacter disease is important for the proper treatment of patients with campylobacter infection. Present tests depend upon culture of viable bacteria and identification by microscopy, which requires care, skill, and two or more days for conclusive results.
Techlab, Inc. |
02/12/15
20150044697 | Outer membrane protein 18 as a diagnostic marker for campylobacter
Accurate and fast detection of the presence of campylobacter disease is important for the proper treatment of patients with campylobacter infection. Present tests depend upon culture of viable bacteria and identification by microscopy, which requires care, skill, and two or more days for conclusive results.
Techlab, Inc. |
02/12/15
20150044693 | Levetiracetam immunoassays
Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.. .
Ark Diagnostics, Inc. |
02/12/15
20150044689 | Diagnostic test for infectious diseases in cattle
The invention relates to an isolated or recombinant protein from the shark heterodontus francisci, which has bovine-erythrocyte-recognition activity and which can bind to sequences of antigens and/or proteins that are characteristic of infectious diseases. Once the aforementioned protein is bound to specific antigens of infectious diseases, it can haemagglutinate upon recognizing the bovine erythrocytes and antibodies characteristic of said diseases, which are present in the active state in biological samples such as whole blood, plasma or serum of bovine origin.
Centro De Investigacion Cientifica Y De Educacion Superior De Ensenad, Baja California (cicese) |
02/12/15
20150044668 | Methods for detection of anti-cytomegalovirus neutralizing antibodies
The present disclosure provides methods useful for determining levels of hcmv infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that hcmv viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus).
Variation Biotechnologies, Inc. |
02/12/15
20150044666 | Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
Methods and kits related to non-equilibrium, ultrasensitive two-site assays for detecting analytes are provided. In one aspect, a two-site assays for detecting analytes under non-equilibrium analyte binding conditions, using low concentrations of reporter specificity molecule (e.g., reporter antibody) and kits for performing the same is provided.
Iris International Inc. |
02/12/15
20150044248 | Polypeptides and their use in treating metapneumovirus (mpv) infection
Polypeptides and compositions thereof are provided for treating or limiting metapneumovirus (mpv) infection, as well as methods for designing such polypeptides. In further aspects, methods of using said isolated polypeptides, vlps or pharmaceutical compositions are provided, which include methods for treating a metapneumovirus (mpv) infection, methods for limiting development of an mpv infection, methods for generating an immune response in a subject, methods for monitoring an mpv-induced disease in a subject and/or monitoring response of the subject to immunization by an mpv vaccine, methods for detecting mpv binding antibodies, methods for producing mpv antibodies, and methods of preventing an mpv infection..
The Scripps Research Institute |
02/12/15
20150044232 | Markers for the responsiveness to anti-cd44 antibodies
The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-cd44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major cd44 isoform in a sample, wherein if the major cd44 isoform is cd44s, the tumor cell or cancer cell is responsive to said anti-cd44 antibody.
Hoffmann-la Roche Inc. |
02/12/15
20150044231 | Therapeutic antibodies
The present invention concerns human antibodies recognising the human c5a receptor. By binding to c5ar the antibodies inhibit c5a signalling, whereby the pro-inflammatory signal is inhibited.
Novo Nordisk A/s |
02/12/15
20150044227 | Methods of treatment with angiopoietin-2 antibodies
The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against angiopoietin-2 (ang-2). Specifically, the disclosure is direct to the use of anti-ang2 antibodies or antigen-binding fragments thereof for treating ischemia.
Medimmune, Llc |
02/12/15
20150044220 | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
Epidermal growth factor receptor (egfr) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased e-cadherin expression at the surface of cancer cells.
Alethia Biotherapeutics Inc. |
02/12/15
20150044216 | Bispecific antibodies
Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scfv) portion. In certain embodiments, the full-size antibody has specificity to egfr and the scfv has specificity to vegf..
Bio-thera Solutions, Ltd. |
02/12/15
20150044215 | Pseudomonas aeruginosa pcrv binding single variable domain antibodies
Polypeptides are provided that are capable of significantly inhibiting andor neutralizing p aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the pcrv protein of p.
Ablynx N.v. |
02/12/15
20150044214 | Bispecific, tetravalent antigen binding proteins
The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche, Inc. |
02/12/15
20150044213 | Protein sustained-release injectable formulation
The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexpla).
Esbatech - A Novartis Company Llc |
02/12/15
20150044212 | Antibodies directed to gpnmb and uses thereof
The present invention provides fully human monoclonal antibodies that specifically bind to gpnmb, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (cdrs) are provided.
Amgen Fremont Inc. |
02/12/15
20150044208 | Modified albumin-binding domains and uses thereof to improve pharmacokinetics
The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility.
Technophage, InvestigaÇÄo E Desenvolvimento Em Biotecnologia, Sa |
02/12/15
20150044197 | Antibodies that specifically bind to the epha2 receptor
The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an epha2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate..
Sanofi |
02/12/15
20150044168 | Treatment of multiple sclerosis with anti-cd19 antibody
The present invention provides for the treatment of multiple sclerosis through the use of chimeric and humanized versions of anti-cd19 antibodies that may mediate adcc, cdc, and/or apoptosis.. .
Medlmmune, Llc |
02/12/15
20150044137 | Neutralizing antibodies to hiv-1 and their use
Neutralizing antibodies that specifically bind to hiv-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided.
The United States Of America, As Represented By The Secretary, Dep. Of Health Care Human Services |